secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0001193125-23-154347
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan reports Phase 1 CLN-619 data: 1 CR, 2 PRs in solid tumors; expansion in endometrial/cervical cancers
--------------------------------------------------------------------------------

- CLN-619 monotherapy showed 1 complete response (parotid gland cancer) and 2 unconfirmed partial responses (endometrial cancer) in heavily pre-treated patients.
- 54% of patients had prior checkpoint inhibitor therapy; responses observed in patients who progressed on prior CPI.
- No dose-limiting toxicities across 0.1-10 mg/kg doses; infusion reactions Grade 1/2 only with pre-medication.
- Based on gynecologic activity, company will initiate monotherapy expansion cohorts in endometrial and cervical cancers.
- Phase 1 trial continues enrolling monotherapy and combination (with pembrolizumab) arms; future results to be shared.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523154347/0001193125-23-154347-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000119312523154347/d462773d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-154347

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer